Tydén G, Nyberg B, Sonnenfeld T, Thulin L
Acta Chir Scand Suppl. 1986;530:43-5.
Prophylactic somatostatin (Stillamin, Serono) was given i.v. to 26 patients for 24 hours (250 micrograms/h) in order to reduce the incidence and severity of hyperamylasemia and pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP). Patients who during the preceding year had been subjected to ERCP served as historical controls. The incidence of hyperamylasemia following ERCP was 58% and 57% in somatostatin-treated patients and controls, respectively. There was no significant difference between the serum amylase levels in the controls and in patients given prophylactic somatostatin. No patient developed clinically overt pancreatitis. It is concluded that prophylactic somatostatin does not reduce the incidence or severity of hyperamylasemia following ERCP.
为降低内镜逆行胰胆管造影术（ERCP）后高淀粉酶血症和胰腺炎的发生率及严重程度，对26例患者静脉注射预防性生长抑素（施他宁，雪兰诺公司生产）24小时（250微克/小时）。将前一年接受过ERCP的患者作为历史对照。ERCP后，生长抑素治疗组患者和对照组患者高淀粉酶血症的发生率分别为58%和57%。对照组和接受预防性生长抑素治疗的患者血清淀粉酶水平无显著差异。无患者发生临床明显的胰腺炎。结论是预防性生长抑素不能降低ERCP后高淀粉酶血症的发生率或严重程度。
